Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Scott

Showing results (1471-1480 of 1,483) with videos related to

Pageof 149
Sort By:
Bioorganic & Medicinal Chemistry Letters|July 12, 2011
Biphenyl/diphenyl ether renin inhibitors: filling the S1 pocket of renin via the S3 pocketJing Yuan, Robert D Simpson, Wei Zhao, et al.
Bioorganic & Medicinal Chemistry Letters|January 13, 2010
Spirocyclic ureas: orally bioavailable 11 beta-HSD1 inhibitors identified by computer-aided drug designColin M Tice, Wei Zhao, Zhenrong Xu, et al.
Journal of Medicinal Chemistry|July 27, 2011
Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase type 1Zhenrong Xu, Colin M Tice, Wei Zhao, et al.
Bioorganic & Medicinal Chemistry Letters|December 5, 2009
Optimization of orally bioavailable alkyl amine renin inhibitorsZhenrong Xu, Salvacion Cacatian, Jing Yuan, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2010
Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1Colin M Tice, Wei Zhao, Paula M Krosky, et al.
Nature Neuroscience|February 23, 2010
Stimulus onset quenches neural variability: a widespread cortical phenomenonMark M Churchland, Byron M Yu, John P Cunningham, et al.
Nature Communications|February 23, 2023
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trialNantia Othonos, Riccardo Pofi, Anastasia Arvaniti, et al.
Neurogenetics|August 29, 2001
Genetic susceptibility to MS: a second stage analysis in Canadian MS familiesD A Dyment, C J Willer, B Scott, et al.
The Lancet. Diabetes & Endocrinology|November 3, 2019
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension studyMichael R McClung, Michelle L O'Donoghue, Socrates E Papapoulos, et al.
Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Pageof 149

Showing results (1471-1480 of 1,483) with videos related to

Sort By:
Pageof 149
Bioorganic & Medicinal Chemistry Letters|July 12, 2011
Biphenyl/diphenyl ether renin inhibitors: filling the S1 pocket of renin via the S3 pocketJing Yuan, Robert D Simpson, Wei Zhao, et al.
Bioorganic & Medicinal Chemistry Letters|January 13, 2010
Spirocyclic ureas: orally bioavailable 11 beta-HSD1 inhibitors identified by computer-aided drug designColin M Tice, Wei Zhao, Zhenrong Xu, et al.
Journal of Medicinal Chemistry|July 27, 2011
Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase type 1Zhenrong Xu, Colin M Tice, Wei Zhao, et al.
Bioorganic & Medicinal Chemistry Letters|December 5, 2009
Optimization of orally bioavailable alkyl amine renin inhibitorsZhenrong Xu, Salvacion Cacatian, Jing Yuan, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2010
Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1Colin M Tice, Wei Zhao, Paula M Krosky, et al.
Nature Neuroscience|February 23, 2010
Stimulus onset quenches neural variability: a widespread cortical phenomenonMark M Churchland, Byron M Yu, John P Cunningham, et al.
Nature Communications|February 23, 2023
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trialNantia Othonos, Riccardo Pofi, Anastasia Arvaniti, et al.
Neurogenetics|August 29, 2001
Genetic susceptibility to MS: a second stage analysis in Canadian MS familiesD A Dyment, C J Willer, B Scott, et al.
The Lancet. Diabetes & Endocrinology|November 3, 2019
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension studyMichael R McClung, Michelle L O'Donoghue, Socrates E Papapoulos, et al.
Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Pageof 149